by

Compass announces promising yet modest results from second Phase 3 psilocybin trial; Missouri hearings on ibogaine and psilocybin bills, New Hampshire psilocybin bill advances

Happy Friday and welcome back to The Microdose, an independent journalism newsletter brought to you by the U.C. Berkeley Center for the Science of Psychedelics.

Compass announces promising yet modest results from second Phase 3 trial

On Tuesday, Compass Pathways announced results from COMP006, its second Phase 3 trial using ...

Continue Reading →
by

Legislative updates in Mississippi, West Virginia, Oregon, and New Hampshire; Fast-tracked federal approval of Compass’s synthetic psilocybin was vetoed; Federal bill proposes VA study psychedelics

Happy Friday and welcome back to The Microdose, an independent journalism newsletter brought to you by the U.C. Berkeley Center for the Science of Psychedelics.

State legislative updates in Mississippi, West Virginia, Oregon, and New Hampshire

On Tuesday, Mississippi’s ibogaine bill, SB 2561, failed to advance out of ...

Continue Reading →

Menu

Blog

Disclaimer

The information on this website is offered for informational use only. MYEBOGA specifically cautions against the use of iboga related products (i) in violation of the law, (ii) without appropriate professional guidance and monitoring, or (iii) without careful personal evaluation of potential risks and hazards. MYEBOGA specifically disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this website. This website does not promote ibogaine services in the R. O. Ireland.

About

This site is 100% voluntary and does not receive any form of payment from any of the providers listed here. In addition, this site does not engage in any way with the supply or manufacture of ibogaine or iboga related products or services. Information is offered for interest only and grew our of a desire to offer a service providing balanced information without any motive for profit.
UA-77446339-1